Cargando…

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

PURPOSE: Diagnosis of malignant mesothelioma is challenging. The first available diagnostic material is often an effusion and biochemical analysis of soluble markers may provide additional diagnostic information. This study aimed to establish a predictive model using biomarkers from pleural effusion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mundt, Filip, Nilsonne, Gustav, Arslan, Sertaç, Csürös, Karola, Hillerdal, Gunnar, Yildirim, Huseyin, Metintas, Muzaffer, Dobra, Katalin, Hjerpe, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749097/ https://www.ncbi.nlm.nih.gov/pubmed/23991032 http://dx.doi.org/10.1371/journal.pone.0072030

Ejemplares similares

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
por: Mundt, Filip, et al.
Publicado: (2014)

Proteome Screening of Pleural Effusions Identifies Galectin 1 as a Diagnostic Biomarker and Highlights Several Prognostic Biomarkers for Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2014)

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy
por: Szulkin, Adam, et al.
Publicado: (2013)

Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma
por: Sato, Tadashi, et al.
Publicado: (2014)

Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
por: Darai-Ramqvist, Eva, et al.
Publicado: (2013)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions
por: Szulkin, Adam, et al.
Publicado: (2014)

Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
por: Kojima, Masataka, et al.
Publicado: (2020)

Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
por: Javadi, Joman, et al.
Publicado: (2021)

Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells
por: Fujihira, Haruhiko, et al.
Publicado: (2021)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma
por: Akgun, Hakan, et al.
Publicado: (2021)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
por: Hillerdal, Carl-Olof, et al.
Publicado: (2017)

MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion
por: Ak, Guntulu, et al.
Publicado: (2015)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
por: Nilsonne, Gustav, et al.
Publicado: (2009)

ERC/mesothelin is expressed in human gastric cancer tissues and cell lines
por: ITO, TOMOAKI, et al.
Publicado: (2014)

Multiplex Soluble Biomarker Analysis from Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2020)

Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma
por: Metintaş, Muzaffer, et al.
Publicado: (2022)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma
por: Ötvös, Rita, et al.
Publicado: (2015)

Inhibitors of cytoskeletal dynamics in malignant mesothelioma
por: Reis, Katarina, et al.
Publicado: (2020)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma Cells
por: Szatmári, Tünde, et al.
Publicado: (2012)

Cytoskeletal Organization Correlates to Motility and Invasiveness of Malignant Mesothelioma Cells
por: Keller, Maureen, et al.
Publicado: (2021)

Rat N-ERC/Mesothelin as a Marker for In Vivo Screening of Drugs against Pancreas Cancer
por: Fukamachi, Katsumi, et al.
Publicado: (2014)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in Mesothelioma Cells
por: Kumar-Singh, Ashish, et al.
Publicado: (2020)

ERC
por: Stambaugh, Wayne, et al.
Publicado: (2022)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Higher concordance of PD‐L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma
por: Mansour, Mohammed S. I., et al.
Publicado: (2021)

Diagnostic and Prognostic Utility of the Extracellular Vesicles Subpopulations Present in Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2021)

Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program
por: Metintaş, Selma, et al.
Publicado: (2017)

ERC report
por: Staff Association
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_3ffm1pq6d2tf6np8u315eimr5h